For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Zevra Therapeutics Inc (NASDAQ: ZVRA) closed at $7.58 in the last session, down -5.96% from day before closing price of $8.06. In other words, the price has decreased by -$5.96 from its previous closing price. On the day, 2.4 million shares were traded. ZVRA stock price reached its highest trading level at $8.215 during the session, while it also had its lowest trading level at $7.24.
Ratios:
We take a closer look at ZVRA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.00 and its Current Ratio is at 2.00. In the meantime, Its Debt-to-Equity ratio is 1.83 whereas as Long-Term Debt/Eq ratio is at 1.81.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on April 02, 2024, Reiterated its Buy rating but revised its target price to $18 from $12 previously.
On March 17, 2023, Maxim Group started tracking the stock assigning a Buy rating and target price of $12.Maxim Group initiated its Buy rating on March 17, 2023, with a $12 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 17 ’24 when Clifton R. LaDuane bought 2,000 shares for $6.77 per share. The transaction valued at 13,540 led to the insider holds 18,469 shares of the business.
Anderson Thomas bought 10,000 shares of ZVRA for $68,065 on Jul 16 ’24. The Director now owns 20,000 shares after completing the transaction at $6.81 per share. On Jul 12 ’24, another insider, Bode John B, who serves as the Director of the company, bought 10,000 shares for $5.87 each. As a result, the insider paid 58,661 and bolstered with 30,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZVRA now has a Market Capitalization of 398842912 and an Enterprise Value of 434309376. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.63 while its Price-to-Book (P/B) ratio in mrq is 9.80. Its current Enterprise Value per Revenue stands at 18.334 whereas that against EBITDA is -6.132.
Stock Price History:
Over the past 52 weeks, ZVRA has reached a high of $8.95, while it has fallen to a 52-week low of $3.89. The 50-Day Moving Average of the stock is 8.28%, while the 200-Day Moving Average is calculated to be 31.48%.
Shares Statistics:
According to the various share statistics, ZVRA traded on average about 920.64K shares per day over the past 3-months and 1313630 shares per day over the past 10 days. A total of 52.62M shares are outstanding, with a floating share count of 52.29M. Insiders hold about 0.63% of the company’s shares, while institutions hold 30.75% stake in the company. Shares short for ZVRA as of 1724976000 were 3832701 with a Short Ratio of 4.16, compared to 1722384000 on 4397553. Therefore, it implies a Short% of Shares Outstanding of 3832701 and a Short% of Float of 7.31.
